Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 7/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920961 | 1.00 | TLR9 (0.50) | TLR9TLR7EGFRPDGFRBEPHA2 | |
| SCHEMBL28507911 | 0.81 | SSTR4 (0.40) | KITIRAK4 | |
| SCHEMBL2798262 | 0.78 | MAP4K4 (0.41) | EPHA2KDREPHB4KITIRAK4 | |
| SCHEMBL30826990 | 0.76 | PARP1 (0.37) | EPHA2KDREPHB4IRAK4MAPK7 | |
| SCHEMBL30618082 | 0.75 | MAP4K4 (0.38) | KITIRAK4MAPK7 | |
| SCHEMBL2918088 | 0.75 | TLR9 (0.76) | TLR9TLR7PDGFRBKIT | |
| SCHEMBL23726611 | 0.73 | TLR9 (0.71) | TLR9TLR7PDGFRBKIT | |
| SCHEMBL30080195 | 0.73 | TLR9 (0.71) | TLR9TLR7PDGFRBKIT | |
| SCHEMBL27620947 | 0.72 | PRMT5 (0.40) | — | |
| SCHEMBL4977833 | 0.71 | PDE3A (0.57) | PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882717-B1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-6750218-B2 | INHIBITORY ACTIVITY ON PHOSPHORYLATION OF PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | MILLENNIUMIUM PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | MATSUNO KENJI (JP) | 2003-12-11 | — | — | US | disclosed |
| US-6472391-B2 | INHIBIT PHOSPHORYLATION OF PDGF RECEPTOR TO HINDER ABNORMAL CELL GROWTH AND CELL WANDERING; TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS. | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6207667-B1 | USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6169088-B1 | FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0882717-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | ERBB4, NPR1, PDGFRB | TLR9 3444/4885TLR7 3569/4885EGFR 11/4885 |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | PDGFRB, MKI67, PDGFRA | TLR9 3520/4885TLR7 3676/4885EGFR 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.